Australian global biotech giant CSL Limited didn’t win the sprint for a coronavirus vaccine. But it may lead the marathon.
The post CSL (ASX:CSL) share price on watch after hints of ‘far more robust’ vaccine appeared first on The Motley Fool Australia. –
The CSL Limited (ASX: CSL) share price is edging higher today, up 0.2% in afternoon trading.
That’s broadly in line with the wider S&P/ASX 200 Index (ASX: XJO), up 0.4% at time of writing.
With a history of generally delivering fairly steady share price growth, 2020 has been unusually volatile for CSL shareholders. While there are various reasons for this, traders jumping in and out of shares based on the latest COVID-19 vaccine news have certainly helped stir this year’s share price volatility.
CSL and the University of Queensland (UQ) have been working collaboratively on a coronavirus vaccine since the outset of the pandemic.
The sprint to the finish line looks to have been won by the mRNA vaccines developed by Moderna Inc (NASDAQ: MRNA), along with the partnered efforts of Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX).
But the experts at CSL and the UQ believe their own efforts may prove more valuable in the long run.
More on that below. But first…
What does CSL do?
CSL is a global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines.
CSL’s operational business segments include CSL Behring and Seqirus. The company operates predominantly in Australia, the United States, Germany, the United Kingdom and Switzerland.
CSL shares first began trading on the ASX in 1994 and today it ranks among the largest companies on the ASX 200. At the current share price, CSL pays a 1% dividend yield, unfranked. The company paid out both dividends for 2020.
Why could CSL’s COVID vaccine prove to be better?
Professor Paul Young is the head of the UQ program developing a COVID vaccine together with CSL.
Addressing their vaccine, Young said (as quoted by the Australian Financial Review):
It is a more traditional vaccine. I think it will be a far more robust vaccine . . . and a better option for the long term. So I still think it’s an important vaccine even though we’re a little bit behind the mRNA vaccines.
Data from the group’s phase 1 trial is expected soon, with phase 2 and 3 trials scheduled to commence in December. Young said if the trials are successful, their vaccine could be ready for wider use in Australia by mid-2021.
Young also highlighted the historic shortage of medicinal manufacturing capabilities in Australia:
Our sovereign capacity is not perhaps what it could have been. Our technology has led into CSL’s technology just beautifully. That was an excellent marriage. But, many of the other vaccine types that could have been developed in Australia haven’t been able to progress because there hasn’t been the infrastructure to take them into the next stage of development.
Although CSL is working on other projects and has numerous successes under its belt, the pending success or failure of its COVID vaccine is likely to have a significant impact on its share price.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- Brokers name 3 ASX shares to buy right now
- Why Pfizer and BioNTech stocks popped Wednesday
- CBA (ASX:CBA) and the ASX banks just had an amazing month
- Why healthcare, tech and consumer staples shares underperformed the ASX 200 in November
- Fund managers are snapping up these ASX stocks at a record pace
Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.